Plain-English translation of NCT06083844 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , when combined with and oral , can help women with high-grade ovarian cancer who still have small amounts of cancer remaining after their initial treatment. The study is looking at whether this combination of three medications can extend the time before cancer returns or progresses. About 20 women will participate in this research at M.D. Anderson Cancer Center.
Many women with ovarian cancer still have traces of disease left after their standard chemotherapy and surgery, even when they appear to be cancer-free. Doctors are studying whether this medication combination can target and eliminate those remaining cancer cells and prevent the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the three medications as part of 21-day treatment cycles. You'll visit the research center regularly for infusions, blood tests, and check-ups to monitor how you're responding and watch for side effects. The study team will also collect and study tissue samples from your previous surgery and blood samples to understand how well the treatment is working and to learn more about your cancer.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States